Next Article in Journal
Hypoxia Promotes Prostate Cancer Aggressiveness by Upregulating EMT-Activator Zeb1 and SK3 Channel Expression
Next Article in Special Issue
Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants
Previous Article in Journal
Evaluating the Performance of a Non-Bonded Cu2+ Model Including Jahn−Teller Effect into the Binding of Tyrosinase Inhibitors
Previous Article in Special Issue
Gender Differences in Developing Biomarker-Based Major Depressive Disorder Diagnostics

Metabolomic Biomarkers in Anxiety Disorders

Department for Psychotherapy and Biopsychosocial Health, Danube University Krems, 3500 Krems, Austria
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(13), 4784;
Received: 26 June 2020 / Revised: 4 July 2020 / Accepted: 5 July 2020 / Published: 6 July 2020
(This article belongs to the Special Issue Biomarkers Guided Diagnosis and Therapy: Toward Precision Psychiatry)
Anxiety disorders range among the most prevalent psychiatric disorders and belong to the leading disorders in the study of the total global burden of disease. Anxiety disorders are complex conditions, with not fully understood etiological mechanisms. Numerous factors, including psychological, genetic, biological, and chemical factors, are thought to be involved in their etiology. Although the diagnosis of anxiety disorders is constantly evolving, diagnostic manuals rely on symptom lists, not on objective biomarkers and treatment effects are small to moderate. The underlying biological factors that drive anxiety disorders may be better suited to serve as biomarkers for guiding personalized medicine, as they are objective and can be measured externally. Therefore, the incorporation of novel biomarkers into current clinical methods might help to generate a classification system for anxiety disorders that can be linked to the underlying dysfunctional pathways. The study of metabolites (metabolomics) in a large-scale manner shows potential for disease diagnosis, for stratification of patients in a heterogeneous patient population, for monitoring therapeutic efficacy and disease progression, and for defining therapeutic targets. All of these are important properties for anxiety disorders, which is a multifactorial condition not involving a single-gene mutation. This review summarizes recent investigations on metabolomics studies in anxiety disorders. View Full-Text
Keywords: metabolomics; metabolites; anxiety; biomarkers metabolomics; metabolites; anxiety; biomarkers
MDPI and ACS Style

Humer, E.; Pieh, C.; Probst, T. Metabolomic Biomarkers in Anxiety Disorders. Int. J. Mol. Sci. 2020, 21, 4784.

AMA Style

Humer E, Pieh C, Probst T. Metabolomic Biomarkers in Anxiety Disorders. International Journal of Molecular Sciences. 2020; 21(13):4784.

Chicago/Turabian Style

Humer, Elke, Christoph Pieh, and Thomas Probst. 2020. "Metabolomic Biomarkers in Anxiety Disorders" International Journal of Molecular Sciences 21, no. 13: 4784.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop